Top-Rated StocksTop-RatedNASDAQ:RARE Ultragenyx Pharmaceutical (RARE) Stock Price, News & Analysis $44.86 -0.20 (-0.44%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$44.41▼$45.9150-Day Range$37.42▼$45.2752-Week Range$31.52▼$54.56Volume604,658 shsAverage Volume807,944 shsMarket Capitalization$3.73 billionP/E RatioN/ADividend YieldN/APrice Target$86.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Ultragenyx Pharmaceutical alerts: Email Address Ultragenyx Pharmaceutical MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.93 Rating ScoreUpside/Downside92.8% Upside$86.50 Price TargetShort InterestBearish5.24% of Shares Sold ShortDividend StrengthN/ASustainability-2.28Upright™ Environmental ScoreNews Sentiment0.55Based on 17 Articles This WeekInsider TradingSelling Shares$536,593 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($6.45) to ($5.19) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.37 out of 5 starsMedical Sector134th out of 936 stocksPharmaceutical Preparations Industry54th out of 436 stocks 4.5 Analyst's Opinion Consensus RatingUltragenyx Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 13 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageUltragenyx Pharmaceutical has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ultragenyx Pharmaceutical's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.24% of the outstanding shares of Ultragenyx Pharmaceutical have been sold short.Short Interest Ratio / Days to CoverUltragenyx Pharmaceutical has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Ultragenyx Pharmaceutical has recently increased by 2.83%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldUltragenyx Pharmaceutical does not currently pay a dividend.Dividend GrowthUltragenyx Pharmaceutical does not have a long track record of dividend growth. Previous Next 3.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreUltragenyx Pharmaceutical has received a 49.22% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for genetic diseases", "Triheptanoin", and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Ultragenyx Pharmaceutical is -2.28. Previous Next 2.5 News and Social Media Coverage News SentimentUltragenyx Pharmaceutical has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Ultragenyx Pharmaceutical this week, compared to 5 articles on an average week.Search InterestOnly 8 people have searched for RARE on MarketBeat in the last 30 days. This is a decrease of -77% compared to the previous 30 days.MarketBeat Follows7 people have added Ultragenyx Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ultragenyx Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $536,593.00 in company stock.Percentage Held by InsidersOnly 5.80% of the stock of Ultragenyx Pharmaceutical is held by insiders.Percentage Held by Institutions97.67% of the stock of Ultragenyx Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ultragenyx Pharmaceutical's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ultragenyx Pharmaceutical are expected to grow in the coming year, from ($6.45) to ($5.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ultragenyx Pharmaceutical is -5.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ultragenyx Pharmaceutical is -5.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioUltragenyx Pharmaceutical has a P/B Ratio of 13.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Ultragenyx Pharmaceutical's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Ultragenyx Pharmaceutical Stock (NASDAQ:RARE)Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.Read More RARE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RARE Stock News HeadlinesJuly 4, 2024 | insidertrades.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Director Corazon (Corsee) D. Sanders Sells 584 SharesJuly 25 at 5:43 PM | finance.yahoo.comUltragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate UpdateJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 24 at 12:55 PM | finance.yahoo.comUltragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research SymposiumJuly 23 at 8:10 AM | americanbankingnews.comUltragenyx Pharmaceutical's (RARE) "Buy" Rating Reaffirmed at Canaccord Genuity GroupJuly 23 at 6:12 AM | americanbankingnews.comUltragenyx Pharmaceutical (NASDAQ:RARE) Receives "Overweight" Rating from Cantor FitzgeraldJuly 22, 2024 | finance.yahoo.comIonis plots next steps for Angelman drug Biogen passed onJuly 22, 2024 | markets.businessinsider.comUnveiling 14 Analyst Insights On Ultragenyx PharmaceuticalJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 22, 2024 | benzinga.comIonis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: AnalystJuly 21, 2024 | americanbankingnews.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives $86.71 Consensus Price Target from AnalystsJuly 20, 2024 | markets.businessinsider.comEvercore ISI Keeps Their Buy Rating on Ultragenyx Pharmaceutical (RARE)July 19, 2024 | globenewswire.comUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)July 19, 2024 | americanbankingnews.comUltragenyx Pharmaceutical (NASDAQ:RARE) Receives "Neutral" Rating from WedbushJune 20, 2024 | globenewswire.comUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 17, 2024 | investorplace.com7 Breakthrough Biotech Stocks for a Shot of Portfolio AdrenalineJune 13, 2024 | globenewswire.comUltragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded WarrantsJune 12, 2024 | globenewswire.comUltragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsSee More Headlines Receive RARE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today7/26/2024Next Earnings (Confirmed)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RARE CUSIPN/A CIK1515673 Webwww.ultragenyx.com Phone(415) 483-8800Fax415-483-8810Employees1,276Year Founded2010Price Target and Rating Average Stock Price Target$86.50 High Stock Price Target$130.00 Low Stock Price Target$45.00 Potential Upside/Downside+92.7%Consensus RatingModerate Buy Rating Score (0-4)2.93 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($8.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-606,640,000.00 Net Margins-138.58% Pretax Margin-139.01% Return on Equity-425.63% Return on Assets-45.88% Debt Debt-to-Equity RatioN/A Current Ratio2.43 Quick Ratio2.28 Sales & Book Value Annual Sales$434.25 million Price / Sales8.59 Cash FlowN/A Price / Cash FlowN/A Book Value$3.35 per share Price / Book13.40Miscellaneous Outstanding Shares83,130,000Free Float78,311,000Market Cap$3.73 billion OptionableOptionable Beta0.56 Social Links 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Emil D. Kakkis M.D. (Age 64)Ph.D., Founder, President, CEO & Director Comp: $1.46MMr. Howard Horn (Age 46)Executive VP of Corporate Strategy & CFO Comp: $184.81kMs. Karah Herdman Parschauer J.D. (Age 46)Chief Legal Officer & Executive VP of Corporate Affairs Comp: $846.74kMr. John Richard Pinion II (Age 58)Chief Quality Operations Officer & Executive VP of Translational Sciences Comp: $860.05kMr. Erik Harris (Age 53)Executive VP & Chief Commercial Officer Comp: $878.77kMr. Theodore A. Huizenga (Age 53)Senior VP, Corporate Controller & Principal Accounting Officer Mr. Ernie W. Meyer (Age 59)Chief Human Resources Officer & Executive VP Mr. Thomas R. Kassberg (Age 64)Chief Business Officer & Executive VP Comp: $714.84kMr. Vimal Srivastava (Age 59)Senior Vice President of Business Development & Alliance Management Mr. Dennis Karl Huang (Age 59)Chief Technical Operations Officer and EVP of Gene Therapy Research & Development Comp: $331.33kMore ExecutivesKey CompetitorsMirati TherapeuticsNASDAQ:MRTXBausch Health CompaniesNYSE:BHCSarepta TherapeuticsNASDAQ:SRPTViatrisNASDAQ:VTRSDr. Reddy's LaboratoriesNYSE:RDYView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpSold 129,713 shares on 7/26/2024Ownership: 0.941%EFG Asset Management North America Corp.Bought 8,725 shares on 7/26/2024Ownership: 0.151%Hennion & Walsh Asset Management Inc.Bought 23,752 shares on 7/20/2024Ownership: 0.088%China Universal Asset Management Co. Ltd.Sold 6,051 shares on 7/20/2024Ownership: 0.012%Oak Ridge Investments LLCBought 19,350 shares on 7/17/2024Ownership: 0.023%View All Insider TransactionsView All Institutional Transactions RARE Stock Analysis - Frequently Asked Questions How have RARE shares performed this year? Ultragenyx Pharmaceutical's stock was trading at $47.82 on January 1st, 2024. Since then, RARE stock has decreased by 6.2% and is now trading at $44.86. View the best growth stocks for 2024 here. How were Ultragenyx Pharmaceutical's earnings last quarter? Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) announced its quarterly earnings data on Thursday, May, 2nd. The biopharmaceutical company reported ($2.03) EPS for the quarter, missing analysts' consensus estimates of ($1.72) by $0.31. The firm's revenue for the quarter was up 8.3% compared to the same quarter last year. What is Emil D. Kakkis' approval rating as Ultragenyx Pharmaceutical's CEO? 41 employees have rated Ultragenyx Pharmaceutical Chief Executive Officer Emil D. Kakkis on Glassdoor.com. Emil D. Kakkis has an approval rating of 88% among the company's employees. Who are Ultragenyx Pharmaceutical's major shareholders? Ultragenyx Pharmaceutical's top institutional investors include Bank of New York Mellon Corp (0.94%), EFG Asset Management North America Corp. (0.15%), Hennion & Walsh Asset Management Inc. (0.09%) and Oak Ridge Investments LLC (0.02%). Insiders that own company stock include Emil D Kakkis, Thomas Richard Kassberg, John Richard Pinion, Dennis Karl Huang, Mardi Dier, Karah Herdman Parschauer, Erik Harris, Eric Crombez, Camille L Bedrosian, Theodore Alan Huizenga and Corazon (Corsee) D Sanders. View institutional ownership trends. How do I buy shares of Ultragenyx Pharmaceutical? Shares of RARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Ultragenyx Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ultragenyx Pharmaceutical investors own include Pfizer (PFE), AbbVie (ABBV), NVIDIA (NVDA), Exelixis (EXEL), Advanced Micro Devices (AMD), Gilead Sciences (GILD) and Micron Technology (MU). This page (NASDAQ:RARE) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ultragenyx Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.